ProfessorJonathanWeber

Fox J, White PJ, Macdonald N, Weber J, McClure M, Fidler S, Ward Het al., 2009, Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men, HIV MEDICINE, Vol: 10, Pages: 432-438, ISSN: 1464-2662

• Author Web Link
• Cite
• Citations: 124

Wilson SL, Scullard G, Fidler SJ, Weber JN, Poulter NRet al., 2009, Effects of HIV status and antiretroviral therapy on blood pressure, HIV MEDICINE, Vol: 10, Pages: 388-394, ISSN: 1464-2662

• Author Web Link
• Cite
• Citations: 21

Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung'u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M, Goulder Pet al., 2009, Adaptation of HIV-1 to human leukocyte antigen class I, NATURE, Vol: 458, Pages: 641-U108, ISSN: 0028-0836

• Author Web Link
• Cite
• Citations: 354

Fox J, Willberg C, Ziprin P, Goldin R, Weber J, McClure M, Klenerman P, Fidler Set al., 2009, The role of the gut mucosa in protection from HIV-1 in highly exposed persistently seronegative individuals (HEPS), HIV MEDICINE, Vol: 10, Pages: 5-5, ISSN: 1464-2662

• Author Web Link
• Cite
• Citations: 1

Fox J, Alsop A, Elam G, Green J, Weber J, Ward H, McClure M, Fidler Set al., 2009, Understanding HIV-risk behaviour in HIV-serodiscordant couples - a novel approach, HIV MEDICINE, Vol: 10, Pages: 54-54, ISSN: 1464-2662

• Author Web Link
• Cite
• Citations: 1

McCormack S, Taylor D, Richardson B, Darbyshire J, Sattentau Q, Karim QA, Karim SSA, Kharsany A, Lacey C, Nunn A, Weber Jet al., 2009, Re: "Enhancement of HIV Infection by Cellulose Sulfate," by Tao <i>et</i> <i>al</i>., AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol: 25, Pages: 373-373, ISSN: 0889-2229

• Author Web Link
• Cite
• Citations: 1

Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, Fryer H, Carrington M, McClure M, Mclean AR, Fidler S, Weber J, Phillips RE, Frater AJet al., 2009, HLA-Associated Clinical Progression Correlates with Epitope Reversion Rates in Early Human Immunodeficiency Virus Infection, JOURNAL OF VIROLOGY, Vol: 83, Pages: 1228-1239, ISSN: 0022-538X

• Author Web Link
• Cite
• Citations: 37

English S, Katzourakis A, Flanagan P, Duda A, Francis J, Matthews P, Prendergast A, Goulder P, Fidler S, Weber J, McClure M, Phillips R, Frater Jet al., 2009, Contemporaneous transmission of genetically distinct HIV variants from a single donor to two recipients, RETROVIROLOGY, Vol: 6, ISSN: 1742-4690

• Author Web Link
• Cite

Midgley CM, Putz MM, Weber JN, Smith GLet al., 2008, Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax, JOURNAL OF GENERAL VIROLOGY, Vol: 89, Pages: 2992-2997, ISSN: 0022-1317

• Author Web Link
• Cite
• Citations: 31

Schmidt C, Kochhar S, Excler J, Smith C, McMichael A, Hanke T, Bwayo J, Jaoko W, Weber J, Kaleebu P, Peters B, Pantaleo G, Vardas E, Vasan S, Keefer M, Ramanathan V, Boyle R, Fast Pet al., 2008, Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA), AIDS Vaccine 2008 Conference, Publisher: MARY ANN LIEBERT INC, Pages: 106-107, ISSN: 0889-2229

• Author Web Link
• Cite

Bart P-A, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, Sheppard NC, Bangala Y, Frachette M-J, Wagner R, Liljestrom P, Kraehenbuhl J-P, Girard M, Goudsmit J, Esteban M, Heeney J, Sattentau Q, McCormack S, Babiker A, Pantaleo G, Weber Jet al., 2008, EV01:: A phase I trial in healthy HIV negative volunteers to evaluate a clade CHIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium, VACCINE, Vol: 26, Pages: 3153-3161, ISSN: 0264-410X

• Author Web Link
• Cite
• Citations: 55

McCormack S, Stohr W, Barber T, Bart P-A, Harari A, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, Burnet S, Legg K, Brodnicki E, Wolf H, Wagner R, Heeney J, Frachette M-J, Tartaglia J, Babiker A, Pantaleo G, Weber Jet al., 2008, EV02:: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone, VACCINE, Vol: 26, Pages: 3162-3174, ISSN: 0264-410X

• Author Web Link
• Cite
• Citations: 79

Gray K, Legg K, Sharp A, Mackie N, Olarinde F, De Souza C, Weber J, Peters Bet al., 2008, Participation in two phase II prophylactic HIV vaccine trials in the UK, VACCINE, Vol: 26, Pages: 2919-2924, ISSN: 0264-410X

• Author Web Link
• Cite
• Citations: 10

Fox J, Scriba TJ, Robinson N, Weber JN, Phillips RE, Fidler Set al., 2008, Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4<SUP>+</SUP> T cell decline following short-course treatment at primary HIV-1 infection, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, Vol: 152, Pages: 532-537, ISSN: 0009-9104

• Author Web Link
• Cite
• Citations: 3

Fox J, Nastouli E, Thomson E, Muir D, McClure M, Weber J, Fidler Set al., 2008, Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom, AIDS, Vol: 22, Pages: 666-668, ISSN: 0269-9370

• Author Web Link
• Cite
• Citations: 30

Fidler S, Fox J, Porter K, Weber Jet al., 2008, Primary HIV infection: to treat or not to treat?, CURRENT OPINION IN INFECTIOUS DISEASES, Vol: 21, Pages: 4-10, ISSN: 0951-7375

• Author Web Link
• Cite
• Citations: 21

Harari A, Bart P-A, Stoehr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl J-P, Esteban M, Heeney J, Frachette M-J, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo Get al., 2008, An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses, JOURNAL OF EXPERIMENTAL MEDICINE, Vol: 205, Pages: 63-77, ISSN: 0022-1007

• Author Web Link
• Open Access Link
• Cite
• Citations: 246

Guimaraes-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J, Barin B, McMichael A, Weber J, Legg K, Babiker A, Hayes P, Gotch F, Smith C, Dally L, Dorrell L, Cebere I, Kay R, Winstone N, Moore S, Goonetilleke N, Fast P, Group ISet al., 2008, Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers, Vaccine, Vol: 26, Pages: 6671-6677, ISSN: 0264-410X

• Publisher Web Link
• Author Web Link
• Cite

Wagner R, Wild J, Bieler K, Wolf H, Mooij P, Heeney J, Weber J, Harrari A, Pantaleo Get al., 2007, Development and immunogenicity of RNA- and codon-optimized HIV candidate Vaccines in phase I clinical trials, 15th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Publisher: MARY ANN LIEBERT INC, Pages: 961-961, ISSN: 1043-0342

• Author Web Link
• Cite

Gantlett KE, Weber JN, Sattentau QJ, 2007, Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides, ANTIVIRAL RESEARCH, Vol: 75, Pages: 188-197, ISSN: 0166-3542

• Author Web Link
• Cite
• Citations: 28

Lucas M, Ulsenheimer A, Pfafferot K, Heeg MHJ, Gaudieri S, Gruener N, Rauch A, Gerlach JT, Jung M-C, Zachoval R, Pape GR, Schraut W, Santantonio T, Nitschko H, Obermeier M, Phillips R, Scriba TJ, Semmo N, Day C, Weber JN, Fidler S, Thimme R, Haberstroh A, Baumert TF, Klenerman P, Diepolder HMet al., 2007, Tracking virus-specific CD4+T Cells during and after acute hepatitis C virus infection, PLOS One, Vol: 2, ISSN: 1932-6203

Background.CD4+T cell help is critical in maintaining antiviral immune responses and such help has been shown to besustained in acute resolving hepatitis C. In contrast, in evolving chronic hepatitis C CD4+T cell helper responses appear to beabsent or short-lived, using functional assays.Methodology/Principal Findings.Here we used a novel HLA-DR1 tetramercontaining a highly targeted CD4+T cell epitope from the hepatitis C virus non-structural protein 4 to track number andphenotype of hepatitis C virus specific CD4+T cells in a cohort of seven HLA-DR1 positive patients with acute hepatitis C incomparison to patients with chronic or resolved hepatitis C. We observed peptide-specific T cells in all seven patients withacute hepatitis C regardless of outcome at frequencies up to 0.65% of CD4+T cells. Among patients who transiently controlledvirus replication we observed loss of function, and/or physical deletion of tetramer+CD4+T cells before viral recrudescence. Insome patients with chronic hepatitis C very low numbers of tetramer+cells were detectable in peripheral blood, compared torobust responses detected in spontaneous resolvers. Importantly we did not observe escape mutations in this key CD4+T cellepitope in patients with evolving chronic hepatitis C.Conclusions/Significance.During acute hepatitis C a CD4+T cellresponse against this epitope is readily induced in most, if not all, HLA-DR1+patients. This antiviral T cell population becomesfunctionally impaired or is deleted early in the course of disease in those where viremia persists.

• Abstract
• Author Web Link
• Open Access Link
• Cite

Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, Weber Jet al., 2007, Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort, AIDS, Vol: 21, Pages: 1283-1291, ISSN: 0269-9370

• Author Web Link
• Cite
• Citations: 24

Deforche K, Camacho R, Grossman Z, Silander T, Soares MA, Moreau Y, Shafer RW, Van Laethem K, Carvalho AP, Wynhoven B, Cane P, Snoeck J, Clarke J, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Cahn P, Brigido LF, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan PR, Shapiro JM, Katzenstein DA, Kantor R, Vandamme A-Met al., 2007, Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors, INFECTION GENETICS AND EVOLUTION, Vol: 7, Pages: 382-390, ISSN: 1567-1348

• Author Web Link
• Cite
• Citations: 27

Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, Morgan D, Beddows S, Weber J, Whitworth JAGet al., 2007, Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D - Results from a rural Ugandan cohort, JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, Vol: 45, Pages: 28-33, ISSN: 1525-4135

• Author Web Link
• Cite
• Citations: 87

Stoehr W, Dunn DT, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson MA, Delpech VC, Phillips AN, Sabin CAet al., 2007, CD4 cell count and initiation of antiretroviral therapy:: trends in seven UK centres, 1997-2003, HIV MEDICINE, Vol: 8, Pages: 135-141, ISSN: 1464-2662

• Author Web Link
• Cite
• Citations: 35

Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD, Abrams DI, Cooper DA, Abrams DI, Cooper DA, Darbyshire JH, Duncan WR, Emery S, Lane HC, Lehrman S, Lundgren JD, Neaton JD, Aguilar L, Betina Angel E, Aquilia S, Belloso W, Benetucci J, Bittar V, Cahn P, Casiro A, Contarelli J, Corral J, Daciuk L, David D, Ferrari I, Fridman D, Galache V, Guaragna G, Ivalo S, Laplume H, Lanusse I, Lasala MB, Lattes R, Lasovsky J, Lopardo G, Losso M, Lourtau L, Lupo S, Maranzana A, Marson C, Massera L, del Lujan Sanchez M, Somenzini C, Tocci M, Algar S, Anderson J, Baker D, Blavius K, Bloch M, Boyle M, Bradford D, Britton P, Carrall L, Carr A, Chuah J, Curry M, D'Arcy-Evans C, Dobson P, Doong N, Egan C, Ferguson W, Finlayson R, French M, Frater A, Gold J, Habel P, Haig K, Holland R, Hyland N, Hoy J, Hudson J, James R, Leung J, Lowe K, MacRae K, McMurchie M, Medland N, Miller S, Murray J, Newman R, Orth D, Patching J, Primrose R, Ree H, Richardson R, Rogers G, Roney J, Roth N, Sarangapany J, Shaw D, Silberberg C, Skett J, Williams L, Soo TM, Sowden D, Street A, Vale R, Villella C, Walker A, Watson A, Wendt N, Wood H, Youds D, Aichelburg A, Rieger A, Vetter N, Clumeck N, De Wit S, Kabeya K, O'Doherty E, Amorim CDS, Basso CR, Lewi DS, Pereira LC, da Silva M, Lobato Souza TN, Angel J, Bouchard P-R, Clark F, Cohen J, Dambreville M, Ellis M, Fiset S, Foster A, Fraser C, Gagnon S, Gilmour J, Guenette R, Haldane H, Hawley-Foss N, Hyndman S, Johnston L, Jubinville N, Juneau F, Kelleher L, LaPointe L, Latendre-Paquette J, Lindemulder A, Mashinter L, Lefebvre E, McFarland N, Morisseau C, O'Neill R, Piche A, Ralph E, Rouleau D, Routy J-P, Sandre R, Schmidt S, Shafran S, Smaill F, Stromberg D, Trepanier J-M, Trottier S, Veal S, Walmsley S, Weiss K, Williams K, Young M, Zaleschuk B, Zarowny D, Baadegaard B, Black F, Boedker K, Gerstoft J, Jensen L, Mathiesen L, Nielsen H, Pedersen C, Petersen D, Aboulker J-et al., 2007, Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2, HIV MEDICINE, Vol: 8, Pages: 112-123, ISSN: 1464-2662

• Author Web Link
• Cite
• Citations: 7

Zimbwa P, Milicic A, Frater J, Scriba TJ, Willis A, Goulder PJR, Pillay T, Gunthard H, Weber JN, Zhang H-T, Phillips REet al., 2007, Precise identification of a human immunodeficiency virus type 1 antigen processing mutant, JOURNAL OF VIROLOGY, Vol: 81, Pages: 2031-2038, ISSN: 0022-538X

• Author Web Link
• Cite
• Citations: 25

Ulsenheimer A, Lucas M, Pfaffero K, Heeg MH, Gaudieri S, Gruener N, Rauch A, Gerlach T, Jung MC, Zachoval R, Pape GR, Santantonio T, Nitschko H, Baumertlo TF, Thimme R, Weber JN, Klenerman P, Diepolder HMet al., 2007, Exhaustion of virus specific CD4+T cells during acute hepatitis C, 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Publisher: ELSEVIER SCIENCE BV, Pages: S295-S295, ISSN: 0168-8278

• Author Web Link
• Cite

Fox J, Dustan S, McClure M, Weber Jet al., 2006, Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy., HIV Med

• Cite

Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H, Babiker A, Rudge P, Usuku K, Osame M, Bangham CR, Weber JNet al., 2006, Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial, Retrovirology, Vol: 3, ISSN: 1742-4690

BackgroundNo therapies have been proven to persistently improve the outcome of HTLV-I-associated myelopathy. Clinical benefit has been reported with zidovudine and with lamivudine in observational studies. We therefore conducted a randomised, double blind, placebo controlled study of six months combination therapy with these nucleoside analogues in sixteen patients.ResultsPrimary outcomes were change in HTLV-I proviral load in PBMCs and clinical measures. Secondary endpoints were changes in T-cell subsets and markers of activation and proliferation.Six patients discontinued zidovudine. No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms. Active therapy was associated with an unexplained decrease in CD8 and non-T lymphocyte counts.ConclusionFailure to detect clinical improvement may have been due irreversible nerve damage in these patients with a long clinical history and future studies should target patients presenting earlier. The lack of virological effect but may reflect a lack of activity of these nucleoside analogues against HTLV-I RT in vivo, inadequate intracellular concentrations of the active moiety or the contribution of new cell infection to maintaining proviral load at this stage of infection may be relatively small masking the effects of RT inhibition.

• Abstract
• Author Web Link
• Open Access Link
• Cite